Lazarus: IT Therapy for ICANS

The goal of this clinical trial is to reduce the duration of ICANS and incidence of G3 or great ICANS in participants who receive axi-cel. The main questions the study aims to answer are: Efficacy of IT therapy to reduce high-grade ICANS in participants who receive axi-cel in NHL compared to historical experience. Researchers will compare Axi-cel to Brexu-cel see if there will be a reduction in ICANS when compared to historical experience.

NCT Number	NCT07763210
Lead Sponsor	Vanderbilt-Ingram Cancer Center Collaborators: Gilead Sciences
Conditions	Non-hodgkin Lymphoma
Enrollment	59 participants
Start Date	2026-10-01
Primary Completion	2029-10-01 (estimated)
Study Completion	2030-10-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-14